GlassScriptPhysician profile
Valentyna Honchar
NPI 1033499462
$5,962.08
in general payments reported to CMS, 2019-2025
47 companies · $1,421 in 2025
The $1,421 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $324 · 2021: $1,438 · 2022: $487 · 2023: $707 · 2024: $1,200 · 2025: $1,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,066 · Consulting Fee: $150 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,066.10 |
| Consulting Fee | $150.00 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,088.40 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Abbvie INC. | $607.60 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $411.81 | 2021-2025 | Ultomiris, Soliris |
| Janssen Pharmaceuticals, INC | $406.94 | 2021-2024 | Xarelto |
| Ucb, INC. | $355.16 | 2023-2025 | Rystiggo, Bimzelx, Zilbrysq |
| Paratek Pharmaceuticals, INC. | $201.35 | 2021 | |
| Eisai INC. | $200.26 | 2023-2025 | |
| Genzyme Corporation | $199.90 | 2019-2021 | |
| Genentech USA, INC. | $176.18 | 2022-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Argenx US, INC. | $164.95 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Teva Pharmaceuticals USA, INC. | $161.48 | 2024-2025 | Austedo Xr, Austedo Xr |
| Amgen INC. | $122.85 | 2021-2022 | |
| Pfizer INC. | $121.12 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $117.00 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $111.24 | 2021 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $104.96 | 2021-2025 | |
| Janssen Biotech, INC. | $102.29 | 2022-2025 | Tremfya |
| Novo Nordisk INC | $101.37 | 2020 | |
| Greenwich Biosciences, INC. | $98.15 | 2020 | |
| Ani Pharmaceuticals, INC. | $96.55 | 2023-2025 | Purified Cortrophin Gel |
| Celgene Corporation | $92.20 | 2024-2025 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $86.35 | 2021 | |
| Tg Therapeutics, INC. | $84.84 | 2024-2025 | |
| Csl Behring | $79.35 | 2024-2025 | Hizentra |
| Neurelis, INC. | $67.75 | 2023-2025 | Valtoco |
| Vanda Pharmaceuticals INC. | $60.08 | 2024-2025 | Ponvory |
| Novartis Pharmaceuticals Corporation | $53.58 | 2020-2021 | |
| Lilly USA, LLC | $49.25 | 2023-2025 | Amyvid, Kisunla, Emgality |
| Genentech, INC. | $45.79 | 2025 | Ocrevus |
| Averitas Pharma INC. | $44.97 | 2025 | Qutenza |
| Cycle Pharmaceuticals INC | $35.94 | 2024-2025 | Bafiertam, Tascenso Odt, Ormalvi |
| Mdd US Operations, LLC | $34.37 | 2024 | Gocovri |
| Sk Life Science, INC. | $32.36 | 2024 | |
| Catalyst Pharmaceuticals, INC. | $24.19 | 2023 | Firdapse |
| Merck Sharp & Dohme LLC | $23.85 | 2024 | Dificid, Zerbaxa |
| Hikma Pharmaceuticals USA | $21.37 | 2021 | |
| Depuy Synthes Sales INC. | $21.06 | 2025 | Monovisc |
| Linus Health, INC. | $18.05 | 2024 | Core Cognitive Evaluation |
| Jazz Pharmaceuticals INC. | $17.79 | 2021 | |
| Ferring Pharmaceuticals INC. | $17.70 | 2024 | Euflexxa |
| Acadia Pharmaceuticals INC | $16.06 | 2024 | Nuplazid |
| Alvogen INC | $15.84 | 2025 | Teriparatide |
| Sandoz INC. | $15.32 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.25 | 2025 | Rexulti |
| Almatica Pharma LLC | $13.90 | 2025 | Teriparatide |
| Sobi, INC | $13.76 | 2025 | |
| Mallinckrodt Hospital Products INC. | $11.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valentyna Honchar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.